Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 98

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 5
Chunk 98
---
 in future periods. We may also incur significant milestone payment obligations to certain of our licensors as our product candidates progress through clinical trials towards potential commercialization.
Acquisition and Integration Related Charges 
In the year ended December 31, 2024, acquisition related charges comprise payments to holders of outstanding ProfoundBio equity awards related to post-combination services. The remaining expenses are integration related charges, which comprise professional fees incurred to assist with the integration of ProfoundBio into our operations post-acquisition. 
See Note 5.5 in our Audited Financial Statements for additional details regarding our acquisition of ProfoundBio. 
Results of Operations
​
Financial Results for the Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023 and Financial Results for the Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022
The information on pages 52-60 in our Annual Report 2024 under the heading “Financial Review” is incorporated herein by reference. 
Significant Accounting Policies
The information in Note 1.1 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference. 
Implementation of New and Revised Standards and Interpretations
The information in Note 1.2 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference.

80

Standards and Interpretations Not Yet in Effect
The information in Note 1.2 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference. 

B.    Liquidity and Capital Resources

The information on pages 58-59 in our Annual Report 2024 under the heading “Liquidity and Capital Resources” is incorporated herein by reference.
The description of our internal and external sources of liquidity, including Genmab’s undrawn unsecured three-year revolving credit facility, in Note 4.1 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference.

The description of our lease obligations in Note 3.3 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference.
The description of our contractual obligations related to a number of agreements, primarily related to research and development activities, in Note 5.3 to our Audited Financial Statements included in our Annual Report 2024 is incorporated herein by reference. 
The description of our contingent commitments under our license and collaboration agreements that may